Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China
Open Access
Abstract
Objectives: This study examines the incidence and risk factors of euglycaemic diabetic ketoacidosis (euDKA) in patients undergoing coronary artery bypass grafting (CABG) and evaluates their postoperative outcomes over a 6-month follow-up period. Design: This study is a single-centre, nested case-control study, conducted in Tianjin, China. Setting: An international cardiovascular hospital. Participants: A total of 1524 patients, with a mean age of 64 (9) years, who underwent isolated elective CABG surgery were reviewed. Primary and secondary outcome measures: Data were extracted from electronic medical records. EuDKA cases were identified by reviewing laboratory examination results until discharge, including arterial blood gas analysis and urine samples. Logistic regression analysis was used in a case-control design to identify potential risk factors of sodium-glucose cotransporter 2 inhibitor (SGLT2i)-associated euDKA. Post-discharge follow-up was conducted through regular outpatient visits. Results: 15 patients with euDKA, all with type 2 diabetes, were identified post-surgery, 13 of whom were SGLT2i users. The cumulative incidence of euDKA within 7 days after surgery was 1% in the cohort, increasing to 7.6% among those who discontinued SGLT2i 1–6 days (n=171) before surgery. A case-control study added seven additional confirmed euDKA patients to the case group, resulting in 20 cases and 95 controls. Univariate regression analysis revealed that the risk of euDKA was 7.304 times higher (95% CI 2.517 to 21.197; p−1 (OR: 6.882, 95% CI 1.822 to 25.997; p=0.004) were associated with a higher risk of euDKA. Compared with controls, euDKA patients experienced a higher rate of type 5 myocardial infarction (6/20 (30%) vs 9/95 (9.5%); p=0.035) and recurrent ketosis post-discharge (3/19 (15.8%) vs 0/87 (0%); p=0.005). Conclusions: This cohort study highlights a notable incidence of euDKA following CABG, particularly among patients using SGLT2i. Close monitoring in the ICU is recommended for patients with intraoperative abnormal blood glucose and pH levels to prevent euDKA.Keywords
Funding Information
- TEDA International Cardiovascular Hospital Research Fund (2021-TD-009 & 2023-TD-1114)
- National Medical Key Discipline (Speciality) Construction Project
This publication has 43 references indexed in Scilit:
- Postoperative Euglycaemic Diabetic Ketoacidosis Associated with Sodium–Glucose Cotransporter-2 Inhibitors (Gliflozins): A Report of Two Cases and Review of the LiteratureAnaesthesia and Intensive Care, 2018
- Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgeryCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2017
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 InhibitorNew England Journal of Medicine, 2017
- SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and DiagnosisClinical Therapeutics, 2016
- Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two casesCritical Care and Resuscitation, 2015
- SGLT inhibition and euglycaemic diabetic ketoacidosisThe Lancet Diabetes & Endocrinology, 2015
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Clinical Pharmacokinetics, 2013
- Hyperglycemic Crises in Adult Patients With DiabetesDiabetes Care, 2009
- Diabetes and Coronary RevascularizationJAMA, 2005
- Euglycaemic Diabetic KetoacidosisBMJ, 1973